mmpc-logo mmpc-logo
twitter-logo @NationalMMPC
| Create Account | login
Publication
Growth hormone treatment does not augment the anti-diabetic effects of
liraglutide in UCD-T2DM rats.
Authors Swarbrick MM, Cox CL, Graham JL, Knudsen LB, Stanhope K, Raun K, Havel PJ
Submitted By Submitted Externally on 3/10/2023
Status Published
Journal Endocrinology, diabetes & metabolism
Year 2023
Date Published 1/1/2023
Volume : Pages 6 : e392
PubMed Reference 36480511
Abstract The incretin hormone glucagon-like peptide-1 (GLP-1) slows gastric emptying,
increases satiety and enhances insulin secretion. GLP-1 receptor agonists, such
as liraglutide, are used therapeutically in humans to improve glycaemic control
and delay the onset of type 2 diabetes mellitus (T2DM). In UCD-T2DM rats, a
model of polygenic obesity and insulin resistance, we have previously reported
that daily liraglutide administration delayed diabetes onset by >4 months.
Growth hormone (GH) may exert anti-diabetic effects, including increasing ß-cell
mass and insulin secretion, while disrupting GH signalling in mice reduces both
the size and number of pancreatic islets. We therefore hypothesized that GH
supplementation would augment liraglutide's anti-diabetic effects., Male
UCD-T2DM rats were treated daily with GH (0.3 mg/kg) and/or liraglutide
(0.2 mg/kg) from 2 months of age. Control (vehicle) and food-restricted (with
food intake matched to liraglutide-treated rats) groups were also studied. The
effects of treatment on diabetes onset and weight gain were assessed, as well as
measures of glucose tolerance, lipids and islet morphology., Liraglutide
treatment significantly reduced food intake and body weight and improved glucose
tolerance and insulin sensitivity, relative to controls. After 4.5 months, none
of the liraglutide-treated rats had developed T2DM (overall p = .019).
Liraglutide-treated rats also displayed lower fasting triglyceride (TG)
concentrations and lower hepatic TG content, compared to control rats. Islet
morphology was improved in liraglutide-treated rats, with significantly
increased pancreatic insulin content (p?treatment tended to increase body weight (and gastrocnemius muscle weight),
there were no obvious effects on diabetes onset or other diabetes-related
outcomes., GH supplementation did not augment the anti-diabetic effects of
liraglutide.




Menu

Home
Contact
About MMPC
Animal Husbandry
Tests Data
Search Data
Analysis
Clients
MMPC Centers

Newsletter

Interested in receiving MMPC News?
twitter-logo Mouse Phenotyping
@NationalMMPC



2017 National MMPC. All Rights Reserved.